Mathers CD, Loncar DProjections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11): 2011-2030

Evidence and Information for Policy Cluster, World Health Organization, Geneva, Switzerland.
PLoS Medicine (Impact Factor: 14). 12/2006; 3(11):e442. DOI: 10.1371/journal.pmed.0030442
Source: PubMed

ABSTRACT Global and regional projections of mortality and burden of disease by cause for the years 2000, 2010, and 2030 were published by Murray and Lopez in 1996 as part of the Global Burden of Disease project. These projections, which are based on 1990 data, continue to be widely quoted, although they are substantially outdated; in particular, they substantially underestimated the spread of HIV/AIDS. To address the widespread demand for information on likely future trends in global health, and thereby to support international health policy and priority setting, we have prepared new projections of mortality and burden of disease to 2030 starting from World Health Organization estimates of mortality and burden of disease for 2002. This paper describes the methods, assumptions, input data, and results.
Relatively simple models were used to project future health trends under three scenarios-baseline, optimistic, and pessimistic-based largely on projections of economic and social development, and using the historically observed relationships of these with cause-specific mortality rates. Data inputs have been updated to take account of the greater availability of death registration data and the latest available projections for HIV/AIDS, income, human capital, tobacco smoking, body mass index, and other inputs. In all three scenarios there is a dramatic shift in the distribution of deaths from younger to older ages and from communicable, maternal, perinatal, and nutritional causes to noncommunicable disease causes. The risk of death for children younger than 5 y is projected to fall by nearly 50% in the baseline scenario between 2002 and 2030. The proportion of deaths due to noncommunicable disease is projected to rise from 59% in 2002 to 69% in 2030. Global HIV/AIDS deaths are projected to rise from 2.8 million in 2002 to 6.5 million in 2030 under the baseline scenario, which assumes coverage with antiretroviral drugs reaches 80% by 2012. Under the optimistic scenario, which also assumes increased prevention activity, HIV/AIDS deaths are projected to drop to 3.7 million in 2030. Total tobacco-attributable deaths are projected to rise from 5.4 million in 2005 to 6.4 million in 2015 and 8.3 million in 2030 under our baseline scenario. Tobacco is projected to kill 50% more people in 2015 than HIV/AIDS, and to be responsible for 10% of all deaths globally. The three leading causes of burden of disease in 2030 are projected to include HIV/AIDS, unipolar depressive disorders, and ischaemic heart disease in the baseline and pessimistic scenarios. Road traffic accidents are the fourth leading cause in the baseline scenario, and the third leading cause ahead of ischaemic heart disease in the optimistic scenario. Under the baseline scenario, HIV/AIDS becomes the leading cause of burden of disease in middle- and low-income countries by 2015.
These projections represent a set of three visions of the future for population health, based on certain explicit assumptions. Despite the wide uncertainty ranges around future projections, they enable us to appreciate better the implications for health and health policy of currently observed trends, and the likely impact of fairly certain future trends, such as the ageing of the population, the continued spread of HIV/AIDS in many regions, and the continuation of the epidemiological transition in developing countries. The results depend strongly on the assumption that future mortality trends in poor countries will have a relationship to economic and social development similar to those that have occurred in the higher-income countries.

  • Source
    • "The age-adjusted survival for breast cancer and cervical cancer is estimated overall to be 57% and 41% in developing countries respectively, compared with 73% and 61% in developed countries [3]. By 2020, 61% of all incident cancer cases are projected to be in developing countries [5]. Radiotherapy refers to the use of ionising radiation in the treatment of malignant and some benign conditions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Cancer is a leading public health problem worldwide. In many developing countries, cancer tends to present in predominantly advanced stages, to a certain extent due to lack of comprehensive screening and poor access to efficient management. This study was carried out to describe the pattern of cancers managed in the Department of Radiotherapy and Oncology in Usmanu Danfodiyo University Teaching Hospital Sokoto, North-western Nigeria. Materials and Methods: This was a cross-sectional descriptive study involving patients with malignancies that attended the new Oncology Department of the Usman Danfodiyo University Teaching Hospital Sokoto, North-West Nigeria for the period of one year (June 2013 – May 2014). The data was analyzed using SPSS (versions 20). Result: A total of 210 patients with complete records met the criteria for the study. Majority 162 (77.1%) were females with a mean age of 45.68±12.4 years. The male patients were 48 (22.9%) with mean age 46.27±16.5. The spectrum of malignant lesions observed were cancer of the cervix 77 (36.67%), breast cancer 74 (35.24%), nasopharyngeal cancer 20 (9.52%), cancer of the larynx 18 (8.57%) and rectal cancer 14 (6.67%). Late presentation was most common with 6 (3%), 101 (49.8%) and 58 (28.6%) patients presenting at stage I, III and IV, respectively. Conclusion: The study demonstrates that Cancer of the cervix is the leading malignancy in the study population.
    Journal of Clinical and Diagnostic Research 08/2015; 9(8):XC01-XC04. DOI:10.7860/JCDR/2015/13892.6379 · 0.23 Impact Factor
  • Source
    • "[1] Mathers et al.'s projections of global mortality estimate 23.3 million deaths by 2030 mainly from heart disease and stroke. [2] Platelet activation is central in the formation of thrombus in the vascular system. Therefore, antiplatelet therapy is crucial in the management of CVDs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: S007-867 is a promising novel antithrombotic agent with better efficacy and lesser bleeding risk than existing agents. The present study investigated the absorption, tissue distribution, and excretion of S007-867 in rat model for further advancement of the molecule. A simple and robust ultra fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) bioanalytical method was used to determine S007-867 in various matrices. Following oral administration, the compound was quickly dispersed in the various tissues and peak concentration levels were achived within 0.5–1 h. Overall, exposure of drug, i.e., AUC in different tissueswas found in the order of small intestine>liver>heart>spleen>lungs>kidney>brain. The total recoveries of the S007-867 within 96 h were 3.36%in urine and faeces. Thismight be due to a first-pass effect by the liver and intestine asmost of the drug was eliminated in metabolite form. These findings provide a crucial information about further development of S007-867 as antithrombotic agent
    Drug Testing and Analysis 07/2015; DOI:10.1002/dta.1811 · 2.82 Impact Factor
  • Source
    • "Cardiovascular disease is the fourth most common cause of death in dogs [1] and one of the most common causes of death in humans [2]. Dilated cardiomyopathy (DCM) is the second most prevalent form of heart disease in dogs, accounting for 10% of cardiac diagnoses [3], and is estimated to be the third most common inherited type of heart disease in humans, reported to affect 35.6 in 100,000 people, although this is thought to be an underestimation [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is a leading cause of death in both humans and dogs. Dilated cardiomyopathy (DCM) accounts for a large number of these cases, reported to be the third most common form of cardiac disease in humans and the second most common in dogs. In human studies of DCM there are more than 50 genetic loci associated with the disease. Despite canine DCM having similar disease progression to human DCM studies into the genetic basis of canine DCM lag far behind those of human DCM. In this review the aetiology, epidemiology, and clinical characteristics of canine DCM are examined, along with highlighting possible different subtypes of canine DCM and their potential relevance to human DCM. Finally the current position of genetic research into canine and human DCM, including the genetic loci, is identified and the reasons many studies may have failed to find a genetic association with canine DCM are reviewed.
    International Journal of Plant Genomics 06/2015; Volume 2015(4). DOI:10.1155/2015/204823
Show more

Preview (2 Sources)

Available from